https://www.prnewswire.com/news-releases/natera-chosen-for-longitudinal-circulating-tumor-dna-study-in-breast-cancer-300547101.html
/PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA testing, has entered into a research collaboration with Imperial College...
circulating tumor dnanaterachosenlongitudinalstudy
https://pubmed.ncbi.nlm.nih.gov/36762756/
LPWGS of ctDNA provides clinically relevant information about the tumor genome in mCRPC patients. Using LPWGS data, we show that high ctDNA% and CNA burden at...
whole genome sequencinglow passprognosticvalue
https://www.precedenceresearch.com/press-release/circulating-tumor-dna-market
The global circulating tumor DNA (ctDNA) market revenue was valued at USD 7.96 billion in 2025 and is expected to attain around USD 24.09 billion by 2033,...
circulating tumor dnamarket insightsctdnaoutlook